Farmakokinetiske / farmakodynamiske forhold Det farmakokinetiske/ farmakodynamiske forhold (PK/ PD) mellem rivaroxaban plasmakoncentrationer og forskellige PD- endepunkter (faktor Xa- hæmning, PT, aPTT, Heptest) er blevet evalueret efter indgivelse i et bredt dosisinterval (5- 30 mg 2 gange dagligt).
10 Pharmacokinetic/ pharmacodynamic relationship The Pharmacokinetic/ pharmacodynamic (PK/ PD) relationship between rivaroxaban plasma concentration and several PD endpoints (Factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg bid).